What is the gastric emptying time (GET)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Gastric transition time, or gastric emptying time, is a critical factor in managing diabetes and other gastrointestinal disorders, and it is essential to understand its variations and influencing factors to optimize treatment outcomes. Gastric emptying time typically ranges from 2 to 4 hours for a standard meal to move from the stomach into the small intestine, as noted in studies on gastrointestinal motility 1. This process varies based on several factors, including meal composition, with liquids emptying faster (20-30 minutes) than solids (3-4 hours) 1. High-fat meals slow gastric emptying significantly, while carbohydrate-rich meals tend to empty more quickly. Physical activity generally accelerates gastric emptying, while stress and anxiety can delay it. Medical conditions like gastroparesis, diabetes, and hypothyroidism can significantly prolong gastric emptying time, as discussed in the context of diabetes management 1.

Some key points to consider in managing gastric transition time include:

  • The importance of dietary modifications to slow gastric emptying, such as increasing dietary fiber and using fat or protein "preloads" before meals 1
  • The role of medications in influencing gastric emptying, with prokinetics like metoclopramide and erythromycin accelerating emptying, and anticholinergics, opioids, and GLP-1 agonists slowing it down 1
  • The need for accurate diagnosis of gastroparesis, using scintigraphy of digestible solids or the 13C octanoic acid breath test, as outlined in recent standards of care for diabetes 1
  • The impact of gastric emptying on glycaemic control, with delayed gastric emptying influencing the delivery and absorption of orally administered drugs and affecting postprandial glycaemia 1

The diagnostic gold standard for gastroparesis is the measurement of gastric emptying with scintigraphy of digestible solids at 15-min intervals for 4 h after food intake, as recommended in the 2025 standards of care for diabetes 1. Understanding gastric transition time is crucial for medication timing, symptom management in digestive disorders, and optimal nutrient absorption, as the stomach's pacemaker cells coordinate the rhythmic contractions that propel food through the digestive tract. By considering these factors and using the most recent and highest-quality evidence, healthcare providers can optimize treatment outcomes for patients with diabetes and other gastrointestinal disorders.

From the FDA Drug Label

Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. Increased rate of stomach emptying has been observed with single oral doses of 10 mg. The answer to the question about gastric transition time is that metoclopramide accelerates gastric emptying.

  • The exact time of gastric transition is not specified in the label. 2

From the Research

Gastric Transition Time

  • Gastric transition time refers to the time it takes for food to empty from the stomach, which can be delayed in conditions such as diabetic gastroparesis 3, 4, 5, 6, 7
  • Diabetic gastroparesis is a state of delayed gastric emptying that affects 20-30% of diabetic patients, causing symptoms such as nausea, early satiety, postprandial bloating and fullness, and vomiting 3
  • The pathophysiology of diabetic gastroparesis involves delayed gastric emptying, which can be managed with drugs that stimulate gastric emptying, such as metoclopramide, domperidone, and cisapride 3, 4, 6
  • Metoclopramide is the only drug approved by the Food and Drug Administration for diabetic gastroparesis, and it acts by stimulating gastric emptying and possessing antiemetic properties 3, 4
  • Other treatments for diabetic gastroparesis include lifestyle modifications, glycemic control, and mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy 5, 6
  • Erythromycin, a macrolide antibiotic and a motilin receptor agonist, has also been shown to stimulate intestinal motility and improve gastric emptying in diabetic gastroparesis patients 7

Factors Affecting Gastric Transition Time

  • Diabetes is the most common known cause of gastroparesis, and poor glycemic control can exacerbate the condition 5
  • Other factors that can affect gastric transition time include the use of certain medications, such as narcotics and anticholinergics, and the presence of other medical conditions, such as gastroesophageal reflux disease and irritable bowel syndrome 5, 6
  • Gastric emptying can be influenced by the type and amount of food consumed, as well as the presence of other symptoms such as nausea and vomiting 3, 7

Measurement of Gastric Transition Time

  • Gastric emptying can be measured using various techniques, including radionuclide methods and breath tests 7
  • The half-time of gastric emptying is a common parameter used to assess gastric emptying, and it refers to the time it takes for half of the meal to empty from the stomach 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Metoclopramide for the treatment of diabetic gastroparesis.

Expert review of gastroenterology & hepatology, 2019

Research

Diabetic Gastroparesis: Principles and Current Trends in Management.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

Research

Diabetic gastroparesis: Therapeutic options.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.